| Trial ID: | L3457 |
| Source ID: | NCT05677334
|
| Associated Drug: |
Henagliflozin
|
| Title: |
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2diabetes
|
| Interventions: |
DRUG: Henagliflozin|DEVICE: Continuous Subcutaneous Insulin Infusion
|
| Outcome Measures: |
Primary: Time percentage (% TIR) in the range of 3.9~10.0 mmol/L blood glucose, Compare the TIR of the two treatment groups, Monitoring 5-14 days | Secondary: Time taken for TIR >70%, Compare the time required for TIR \>70% of the two groups, 5-14 days after treatment|Mean Amplitude of Glycemic Excursions (MAGE), Compare the mage of the two treatment groups, 5-14 days after treatment|time below range (TBR), Compare the TBR of the two treatment groups, 5-14 days after treatment|total insulin dosage, Compare the total insulin dosage of the two treatment groups, 5-14 days after treatment|time above range (TAR), Compare the TAR of the two treatment groups, 5-14 days after treatment
|
| Sponsor/Collaborators: |
Sponsor: First Affiliated Hospital of Guangxi Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
210
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-03-01
|
| Completion Date: |
2024-10-30
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-12
|
| Locations: |
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05677334
|
